Since their launch in 2014, they have repeatedly published various anti-day clinical data in the form of super dark horses, and have also been approved for a variety of cancer indications, including malignant melanoma, non-small cell lung cancer, renal cell carcinoma, and Hodge. Gold lymphoma, head and neck cancer and bladder cancer are intensifying.